New CFO at Mylan
pharmafile | May 3, 2016 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Mylan, cfo, kenneth parks
Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016.
Parks boasts more than 30 years of corporate finance experience, including responsibilities across financial planning, accounting, investor relations, treasury, tax and information technology.
He currently services as chief financial officer at electronics provider WESCO International. Previously, he held senior roles at United Technologies Corporation, including vice president, finance, at the $7 billion UTC Fire and Security division, and director of investor relations.
At Mylan, Parks will be responsible for all of Mylan’s global finance functions including accounting and control, financial planning and analysis, investor relations, treasury and tax.
Mylan CEO Heather Bresch says: “Ken is a proven finance leader with an impressive track record operating in complex, global cultures and manufacturing environments. He has extensive experience working in a public company setting, including capabilities developing strong relationships with investors and financial analysts.
“Ken has successfully led organisations through numerous periods of change, including overseeing significant acquisitions, expansion into emerging markets and restructurings. In addition to his strong experience and leadership capabilities, Ken brings to Mylan deep functional expertise and technical knowledge and we believe he will be a great asset to our business and finance team.”
Parks comments: “Mylan’s dynamic business and unique culture, strong track record of growth and value-creation, and exciting outlook for the future make this an exceptional opportunity. I look forward to joining Mylan’s leadership team and working with Mylan’s experienced finance organization to bring value to the organization and contribute to its future success in providing the world’s population with access to high quality medicine.”
The news comes following the announcement of Mylan’s Q1 results, which saw a 17% rise in revenue and the maintaining of the company’s full year outlook.
Related Content
Pfizer to pay $345 million in EpiPen lawsuit
Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …
Mylan reaches agreement with Aspen for their European thrombosis business
Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …
Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …
